Image 1 of 1
Reta pen 40mg
Retatrutide—a triple agonist of GLP1, GLP, and Glucagon Receptors.
Retatrutide, a new weight loss medicine. As the only injection to support weight loss in three ways, Retatrutide could be revolutionary in this space.
GLP-1 medication can be stored unrefrigerated at temperatures not above 30 degrees Celsius for up to 30 days.
Store in a refrigerator; do not freeze
Retatrutide has been nicknamed ‘Triple G’. This is because it targets three different receptors and hormones—GLP-1, glucagon, and GIP (1). Glucagon and GIP are naturally released when you eat food and play a role in reducing appetite, lowering blood sugar, and helping the body burn fat (1).
This means Retatrutide can support people to reduce weight in three ways:
Suppress appetite and slow digestion, meaning you’re not as hungry as often and feel fuller for longer
Increase fat metabolism, so your body breaks down fat quicker
Increase insulin sensitivity, which reduces blood sugar, causing the body to break down stored fat
Currently, Wegovy and Mounjaro injections are available to support weight loss.
Whilst Wegovy targets GLP-1 and Mounjaro targets GLP-1 and GIP (4), neither targets glucagon receptors. This means that retatrutide, with three targets, could be more effective (1).
Testing has already shown that Retatrutide can help participants lose more weight in a shorter amount of time (1). Studies show that Retatrutide has achieved 24% weight loss in less than a year (48 weeks) (1). This is the highest percentage of weight loss ever recorded in a trial for an obesity drug.
Over a longer period of time (72 weeks), Mounjaro has shown a 22% loss in weight, and Wegovy has shown 17% (4). This is also more than another upcoming injection, CagriSema, which has shown 23% weight loss in over a year (68 weeks).
How is Retatrutide administered?
Retatrutide is given using a pen injector (1). It is delivered as a subcutaneous injection into the arm, thigh, or stomach (1). It is expected to be administered weekly, starting with a lower dose to minimise side effects.
What are the side effects of retatrutide?
Retatrutide has some common side effects (1), similar to Wegovy and Mounjaro, including:
Nausea
Vomiting
Constipation
Diarrhoea
Since retatrutide can help increase weight loss in an additional way to Wegovy and Mounjaro, these side effects could be more intense (1). They can be managed by using the injection when you eat, drinking plenty of water, and getting enough fiber in your diet (6).
Each box contains:
1 Pen of 4 x 10mg doses
12 disposable needles
1 instruction booklet
Not recommended for those with pancreatitis problems—always talk to your doctor
Available in 20mg, 40mg, 60mg & 120mg
Retatrutide—a triple agonist of GLP1, GLP, and Glucagon Receptors.
Retatrutide, a new weight loss medicine. As the only injection to support weight loss in three ways, Retatrutide could be revolutionary in this space.
GLP-1 medication can be stored unrefrigerated at temperatures not above 30 degrees Celsius for up to 30 days.
Store in a refrigerator; do not freeze
Retatrutide has been nicknamed ‘Triple G’. This is because it targets three different receptors and hormones—GLP-1, glucagon, and GIP (1). Glucagon and GIP are naturally released when you eat food and play a role in reducing appetite, lowering blood sugar, and helping the body burn fat (1).
This means Retatrutide can support people to reduce weight in three ways:
Suppress appetite and slow digestion, meaning you’re not as hungry as often and feel fuller for longer
Increase fat metabolism, so your body breaks down fat quicker
Increase insulin sensitivity, which reduces blood sugar, causing the body to break down stored fat
Currently, Wegovy and Mounjaro injections are available to support weight loss.
Whilst Wegovy targets GLP-1 and Mounjaro targets GLP-1 and GIP (4), neither targets glucagon receptors. This means that retatrutide, with three targets, could be more effective (1).
Testing has already shown that Retatrutide can help participants lose more weight in a shorter amount of time (1). Studies show that Retatrutide has achieved 24% weight loss in less than a year (48 weeks) (1). This is the highest percentage of weight loss ever recorded in a trial for an obesity drug.
Over a longer period of time (72 weeks), Mounjaro has shown a 22% loss in weight, and Wegovy has shown 17% (4). This is also more than another upcoming injection, CagriSema, which has shown 23% weight loss in over a year (68 weeks).
How is Retatrutide administered?
Retatrutide is given using a pen injector (1). It is delivered as a subcutaneous injection into the arm, thigh, or stomach (1). It is expected to be administered weekly, starting with a lower dose to minimise side effects.
What are the side effects of retatrutide?
Retatrutide has some common side effects (1), similar to Wegovy and Mounjaro, including:
Nausea
Vomiting
Constipation
Diarrhoea
Since retatrutide can help increase weight loss in an additional way to Wegovy and Mounjaro, these side effects could be more intense (1). They can be managed by using the injection when you eat, drinking plenty of water, and getting enough fiber in your diet (6).
Each box contains:
1 Pen of 4 x 10mg doses
12 disposable needles
1 instruction booklet
Not recommended for those with pancreatitis problems—always talk to your doctor
Available in 20mg, 40mg, 60mg & 120mg